进行性硬纤维瘤:放射组学与常规疗效标准预测全身治疗期间疾病进展的比较——法国肉瘤组多中心研究
本研究回顾性纳入42例进行性硬纤维瘤患者,基于基线与化疗第一周期后早期MRI提取放射组学特征构建评分,用于预测无进展生存期。放射组学评分与PFS独立相关(校正HR=5.60,p=0.003),而RECIST 1.1等常规疗效标准均未独立相关;放射组学模型一致性指数最高(0.84;95%CI 0.71-0.96)。
要点
- 放射组学评分高提示预后差,与PFS独立相关(校正HR=5.60,p=0.003)。
- 常规疗效标准(mRECIST、EASL、Cheson、Choi、修订Choi)均未与PFS独立相关。
- 放射组学模型预测PFS的一致性指数为0.84(95%CI 0.71-0.96),高于各常规标准。
核心结论
- 通过专用放射组学评分量化肿瘤异质性的早期变化,可能改善接受化疗的硬纤维瘤患者的疗效评估。
研究设计与样本
- 回顾性多中心研究,纳入42例进行性硬纤维瘤患者(中位年龄38.2岁),均有基线MRI(MRI-0)及第一周期化疗后早期MRI(MRI-1,距首周期化疗平均3个月,SD 28天)。
- 在脂肪抑制增强T1加权成像上对硬纤维瘤体积进行分割,经信号强度归一化、体素尺寸标准化和离散化后,提取90个基线及变化量三维放射组学特征。
- 采用交叉验证和最小绝对收缩与选择算子惩罚Cox回归生成放射组学评分,并以一致性指数评估各模型从MRI-0到MRI-1预测无进展生存期(按RECIST 1.1定义)的性能。
- 结果对体力状态、肿瘤体积、既往化疗、当前化疗及β-catenin突变进行了校正。
关键影像表现/征象
- MRI可在肿瘤发生尺寸变化之前显示应答肿瘤异质性的早期改变,源于细胞区域减少和纤维坏死内容增加。
诊断标准与关键数值
- 放射组学评分包含4个变量,高评分提示预后不良。
- 放射组学评分与PFS独立相关(校正HR=5.60,p=0.003),而mRECIST、EASL、Cheson、Choi及修订Choi标准均未与PFS独立相关。
- 基于放射组学评分的预后模型一致性指数最高(0.84;95%CI 0.71-0.96)。
临床应用与阅片要点
- 对进行性硬纤维瘤患者,可在基线和化疗第一周期后早期MRI上提取放射组学特征并计算评分,辅助预测无进展生存期。
- 常规RECIST 1.1等尺寸或密度标准在本研究中未独立预测PFS,阅片时可关注肿瘤异质性的早期变化而非仅依赖尺寸。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE. The response of desmoid tumors (DTs) to chemotherapy is evaluated with Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) in daily practice and clinical trials. MRI shows early change in heterogeneity in responding tumors due to a decrease in cellular area and an increase in fibronecrotic content before dimensional response. Heterogeneity can be quantified with radiomics. Our aim was to develop radiomics-based response criteria and to compare their performances with clinical and radiologic response criteria. MATERIALS AND METHODS. Forty-two patients (median age, 38.2 years) were included in this retrospective multicenter study because they presented with progressive DT and had an MRI examination at baseline, which we refer to as "MRI-0," and an early MRI evaluation performed after the first chemotherapy cycle (mean time after first chemotherapy cycle, 3 months [SD, 28 days]), which we refer to as "MRI-1." After signal intensity normalization, voxel size standardization, discretization, and segmentation of DT volume on fat-suppressed contrast-enhanced T1-weighted imaging, 90 baseline and delta 3D radiomics features were extracted. Using cross-validation and least absolute shrinkage and selection operator-penalized Cox regression, a radiomics score was generated. The performances of models based on the radiomics score, modified Response Evaluation Criteria in Solid Tumors, European Association for the Study of the Liver criteria, Cheson criteria, Choi criteria, and revised Choi criteria from MRI-0 to MRI-1 to predict progression-free survival (PFS, as defined by RECIST 1.1) were assessed with the concordance index. The results were adjusted for performance status, tumor volume, prior chemotherapy, current chemotherapy, and β-catenin mutation. RESULTS. There were 10 cases of progression. The radiomics score included four variables. A high score indicated a poor prognosis. The radiomics score independently correlated with PFS (adjusted hazard ratio = 5.60, p = 0.003), and none of the usual response criteria independently correlated with PFS. The prognostic model based on the radiomics score had the highest concordance index (0.84; 95% CI, 0.71-0.96). CONCLUSION. Quantifying early changes in heterogeneity through a dedicated radiomics score could improve response evaluation for patients with DT undergoing chemotherapy.
引用
- Crombé A, Kind M, Ray-Coquard I, et al. Progressive Desmoid Tumor: Radiomics Compared With Conventional Response Criteria for Predicting Progression During Systemic Therapy-A Multicenter Study by the French Sarcoma Group. AJR Am J Roentgenol. 2020. PMID: 32991215. doi:10.2214/AJR.19.22635
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。